Does laser inactivate botulinum toxin?

Dermatologic Surgery

Volumn 31, Issue 4, 2005, Pages 399-404

  Semchyshyn, Natalie L ^a,b   Kilmer, Suzanne L ^a  

^a Laser and Skin Surgery Center of Northern California   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN;

ACETYLCHOLINE RELEASE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEVICE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GLABELLAR FROWN LINE; HUMAN; INTESNE PULSE LIGHT; LOW LEVEL LASER THERAPY; NEUROMUSCULAR SYNAPSE; PERIORBITAL CROW FOOT; PHOTOTHERAPY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RADIOFREQUENCY; SKIN DEFECT;

EID: 16844387025     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042728-200504000-00005     Document Type: Article

References (14)

1. Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg 2001;20:71-84.
2. Carruthers J, Carruthers A. Botox use in the mid and lower face and neck. Semin Cutan Med Surg 2001;20:85-92.
3. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000;43:249-59.
4. Ahmed SA, Smith LA. Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active. J Protein Chem 2000;19:475-87.
5. Bandyopadhyay S, Clark AW, DesGupta BR, Sathyamoorthy V. Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J Biol Chem 1987;262:2660-3.
6. Simpson LL, Maksymowych AB, Park JB, Bora RS. The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. J Pharmacol Exp Ther 2004;308:857-64.
7. Rostan E, Bowes LE, Iyer S, Fitzpatrick RE. A double-blind, side-by-side comparison study of low fluence long pulse dye laser to coolant treatment for wrinkling of the cheeks. J Cosmet Laser Ther 2001;3:129-36.
8. Goldberg DJ, Rogachefsky AS, Silapunt S. Non-ablative laser treatment of facial rhytides: a comparison of 1450-nm diode laser treatment with dynamic cooling as opposed to treatment with dynamic cooling alone. Lasers Surg Med 2002;30:79-81.
9. Goldberg DJ, Cutler KB. Nonablative treatment of rhytids with intense pulsed light. Lasers Surg Med 2000;26:196-200.
10. Zelickson BD, Kist D, Bernstein E, et al. Histological and ultrastructural evaluation of the effects of a radiofrequency-based nonablative dermal remodeling device: a pilot study. Arch Dermatol 2004;140:204-9.
11. Carruthers J, Carruthers A. The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet botulinum toxin type A chemodenervation. Dermatol Surg 2004;30:355-66.
12. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 1997;48:249-53.
13. Trindade De Almeida AR, Kadunc BV, et al. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg 2003;29:530-1; discussion 532.
14. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 2002;138:510-4.